The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines ∗ —Anticoagulation During Cardiopulmonary Bypass
- 1 February 2018
- journal article
- research article
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 105 (2) , 650-662
Abstract
No abstract availableKeywords
This publication has 111 references indexed in Scilit:
- Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid antifibrinolytic therapyPerfusion, 2013
- Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced ThrombocytopeniaThrombosis Journal, 2013
- Guidelines on the diagnosis and management of heparin‐induced thrombocytopenia: second editionBritish Journal of Haematology, 2012
- Treatment and Prevention of Heparin-Induced ThrombocytopeniaChest, 2012
- Challenges encountered with argatroban anticoagulation during cardiopulmonary bypassJournal of Anaesthesiology Clinical Pharmacology, 2012
- Heparin Concentration–Based Anticoagulation for Cardiac Surgery Fails to Reliably Predict Heparin Bolus Dose RequirementsAnesthesia & Analgesia, 2010
- Effect of Modified Ultrafiltration on Bivalirudin Elimination and Postoperative Blood Loss After On‐Pump Coronary Artery Bypass Grafting: Assessment of Different Filtration StrategiesJournal of Cardiac Surgery, 2008
- Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentrationPerfusion, 2006
- A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON studyThe Journal of Thoracic and Cardiovascular Surgery, 2006
- Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?The Journal of Thoracic and Cardiovascular Surgery, 2004